Undaunted Bio
Seed-stage biotechnology company focused on repurposing existing drugs for neuropathic pain. Uses a clinically informed, AI-driven, network-medicine approach combined with cell-based models and medicinal chemistry to interrogate mechanism of action, reformulate a lead repurposed candidate into an oral thin film, and advance toward IND-enabling studies and human trials via the FDA 505(b)(2) pathway.
Industries
N/A
Nr. of Employees
small (1-50)
Undaunted Bio
Products
Repurposed drug reformulated as oral thin film for trigeminal neuralgia (lead candidate)
A repurposed clinical-stage compound being reformulated into an oral thin film dosage form for treatment of trigeminal neuralgia and other neuropathic pain indications; currently pre-IND and being developed via the FDA 505(b)(2) pathway.
Repurposed drug reformulated as oral thin film for trigeminal neuralgia (lead candidate)
A repurposed clinical-stage compound being reformulated into an oral thin film dosage form for treatment of trigeminal neuralgia and other neuropathic pain indications; currently pre-IND and being developed via the FDA 505(b)(2) pathway.
Services
Preparation and sharing of investor materials and engagement with advisors and collaborators to support seed fundraising and development milestones.
Preparation and sharing of investor materials and engagement with advisors and collaborators to support seed fundraising and development milestones.
Expertise Areas
- Drug repurposing for neuropathic pain
- AI-driven drug discovery and knowledge-graph analytics
- Preclinical model development for neuropathic pain
- Formulation development (oral thin film)
Key Technologies
- Large language models (LLMs)
- Knowledge graphs
- Network medicine / graph-based analysis
- Cell-based neuropathic pain assays
News & Updates
Investor pitch deck and one-page investor summary available for download to potential investors.
Clinical effectiveness observed in off-label/compassionate use and an n-of-1 evaluation demonstrating reversal of trigeminal neuralgia pain, used to inform development.
On track to commence human trials in early 2026 with an intended approval objective by 2029 using the FDA 505(b)(2) pathway.
Investor pitch deck and one-page investor summary available for download to potential investors.
Clinical effectiveness observed in off-label/compassionate use and an n-of-1 evaluation demonstrating reversal of trigeminal neuralgia pain, used to inform development.
On track to commence human trials in early 2026 with an intended approval objective by 2029 using the FDA 505(b)(2) pathway.